New Nordic Healthbrands (NNH) Q4 2025 earnings summary

Executive summary

• Net revenue increased by 4.7% year-over-year to SEK 576.4 million, with local currency growth of 9.6%.

• Operating profit improved to SEK 15.1 million from SEK -4.4 million year-over-year.

• Profit after tax rose to SEK 8.2 million from SEK -7.7 million, with EPS at SEK 1.32 versus SEK -1.24.

• Growth was driven by successful product launches and strong performance in Europe.

• Cost reductions and improved inventory management contributed to profitability.

Financial highlights

• Q4 net revenue was SEK 150.6 million, up 0.6% year-over-year; local currency growth was 8%.

• Gross margin for the year was 64.3% (down from 64.5%), with gross profit at SEK 370.4 million.

• EBITDA for the year improved to SEK 17.6 million from SEK -1.8 million.

• Cash flow from operating activities for the year was SEK 8.4 million, up from SEK -5.4 million.

• Equity increased to SEK 103.5 million, with an equity ratio of 42.0%.

Outlook and guidance

• Continued focus on profitable growth, product innovation, and expanding distribution.

• New product launches planned for 2026, including longevity supplements and GLP-1-related products.

• Expansion into new markets such as Mexico, South Korea, Chile, and Turkey expected in 2026.

• Anticipated further improvements in profitability and earnings per share in 2026.